Synaptogenix Inc (SNPX): Interim Data Anticipated Q1 2017 Ne...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	481
Posts	60445
Boards Moderated	18
Alias Born	09/20/2001

XenaLives

Re: None

Monday, 12/05/2016 11:05:16 AM

Monday, December 05, 2016 11:05:16 AM

Interim Data Anticipated Q1 2017

Neurotrope, Inc. (NTRP) today announced that the first patients have been dosed in the Company’s Phase 2b clinical trial of its lead candidate, Bryostatin-1, for the treatment of advanced Alzheimer’s disease.

“We believe that Bryostatin represents a new and disruptive technology in what has been an unsuccessful war against Alzheimer’s disease. This trial seeks to statistically verify preliminary results seen in compassionate use patients and patients treated in our completed Phase 2a study,” said Charles S. Ramat, President and CEO of Neurotrope. “We are excited at being on the cusp of providing a meaningful treatment to this suffering, severely impaired population and their caregivers.”

http://www.news-medical.net/news/20160216/First-patients-dosed-in-Neurotropes-Bryostatin-1-Phase-2b-trial-for-treatment-of-advanced-Alzheimere28099s-disease.aspx

This is from February 16th, any peer reviewed papers on these "preliminary results"?

In Peace, In War